Ann: Change of Director's Interest Notice - R, page-9

re: Ann: Change of Director's Interest No... Straight comparisons like that aren't enough, there's a lot more behind the scenes such as management ability, marketability of the company and it's products, track record for delivery, product risk profile, etc

Equally, share price comparsions don't work either, as pointed out by peaceAKKI - market caps matter

ANP suffered at the hands of the Kynamro safety challenges, but ANP has been subtely (and respectfully) distancing it's own results to those of ISIS / Kynamro and Mark's made it clear that their approach is different, and that he expects a better outcome

Remember that ANP was in fact holding up decent SP levels until the Kynamro setbacks, so while yes, 80% of ANP's SP appreciate will happen in a massive surge if they deliver good results in trials etc, it sure as hell doesn't deserve to be sub 1c, and it wouldn't have been, if it weren't for Kynamro

ISIS link here is both a blessing and a curse and more often a curse, as we see unnecessary downside through the link if ISIS suffers poor results/updates, btu see no upside whatsoever as ISIS SP continues to surge over the last 6 months

Management is top notch and back up their business with professional updates and results, and now, their own cash which is obviously partly designed to send a comforting message to the market, which is awesome stuff